Vai al contenuto principale della pagina
Autore: |
Irving Peter
![]() |
Titolo: |
Clinical Dilemmas in Inflammatory Bowel Disease : New Challenges
![]() |
Pubblicazione: | Hoboken, : Wiley, 2011 |
Edizione: | 2nd ed. |
Descrizione fisica: | 1 online resource (286 p.) |
Disciplina: | 616.344 |
Soggetto topico: | Clinical dilemmas |
Inflammatory bowel diseases | |
Inflammatory Bowel Diseases | |
Inflammatory bowel diseases - Decision making | |
Inflammatory bowel diseases -- Decision making | |
Intestinal Diseases | |
Gastroenteritis | |
Gastrointestinal Diseases | |
Digestive System Diseases | |
Diseases | |
Medicine | |
Health & Biological Sciences | |
Gastroenterology | |
Altri autori: |
SiegelCorey A
![]() ![]() ![]() |
Note generali: | Description based upon print version of record. |
Nota di contenuto: | Clinical Dilemmas inInflammatoryBowel Disease; Contents; Contributors; Preface; Part I: Genes and Phenotype in IBD; 1 Which will take us further in IBD-study of coding variation or epigenetics?; 2 IBD in different ethnic groups: same or different?; Part II: Bugs and IBD-Good, Bad, or Indifferent?; 3 How does the risk of infection influence management of IBD around the world?; 4 Traveling with IBD; 5 What to do about hepatitis B and hepatitis C in patients with IBD; 6 CMV in IBD-passenger or pathogen?; 7 Clostridium difficile in IBD: impact, prevention, and treatment |
8 Prebiotics and synbiotics: panacea or placebo9 Worms: light at the end of their burrow; 10 Do we really need to vaccinate all patients with IBD?; Part III: Investigating IBD; 11 Biomarkers in IBD: myth or marvel?; 12 Radiation exposure in IBD: how do we minimize the dangers?; 13 Surveillance colonoscopy in UC: what is the best way to do it?; Part IV: Medical Therapy; 5-ASA; 14 New 5-ASAs for ulcerative colitis: a tiny step or giant stride forward?; 15 Do 5-ASAs prevent cancer?; 16 Why do we still use 5-ASAs in Crohn's disease?; Steroids | |
17 Steroids in Crohn's disease: do the benefits outweigh the dangers?Immunomodulators; 18 Thioguanine nucleotide measurement: nonadherent, underdosed, shunter, or refractory?; 19 Thiopurines and the sun: what should be done?; 20 Do thiopurines worsen risk and prognosis of cervical neoplasia?; 21 Optimizing use of methotrexate; 22 Which calcineurin inhibitor and when?; Biologics; 23 Are all anti-TNF agents the same?; 24 One drug or two: do patients on biologics need concurrent immunomodulation?; 25 How do we identify patients needing early aggressive therapy and what should we use? | |
26 What is the role of biologics in UC?27 What can we do with Crohn's patients who fail or lose response to anti-TNF therapy?; 28 Which extraintestinal manifestations of IBD respond to biologics?; 29 Use and abuse of biologics in pregnancy; 30 Is anti-TNF therapy safe to use in people with a history of malignancy?; 31 The risks of immunomodulators and biologics: what should we tell patients?; 32 When, how, and in whom should we stop biologics?; Part V: Other Treatments; 33 Avoiding drug interactions | |
34 Is there still a role for ursodeoxycholic acid treatment patients with inflammatory bowel disease associated with primary sclerosing cholangitis?35 Stem cell transplantation for Crohn's: will it fulfill its promise?; 36 Complementary therapy: is there a needle in the haystack?; Part VI: Surgical Dilemmas in IBD; 37 Optimizing IBD patients for surgery and recovery; 38 Is surgery the best initial treatment for limited ileocecal Crohn's disease?; 39 Laparoscopic or open surgery for IBD?; 40 Optimizing management of perianal Crohn's disease | |
41 Does anti-TNF therapy increase the risk of complications of surgery? | |
Sommario/riassunto: | The second edition of Clinical Dilemmas in Inflammatory Bowel Disease: New Challenges, is a practical, up-to-date handbook providing expert guidance on specific clinical dilemmas and areas of difficulty that the gastroenterologist regularly faces in day-to-day practice. In this new edition, 75% of the "dilemmas" are brand new dilemmas facing the IBD specialist concerning emerging treatment therapies, such as the use of cannabinoids and Viagra for Crohn's disease. The remaining 25% of the dilemmas are fully updated from the previous edition, incorporating the latest clinical thinking |
Titolo autorizzato: | Clinical Dilemmas in Inflammatory Bowel Disease ![]() |
ISBN: | 1-283-24049-1 |
9786613240491 | |
1-4443-4257-6 | |
1-4443-4254-1 | |
Formato: | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione: | Inglese |
Record Nr.: | 9910139555703321 |
Lo trovi qui: | Univ. Federico II |
Opac: | Controlla la disponibilità qui |